The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Intratumoral (i.t.) IMO-2125 (IMO), a TLR9 agonist, in combination with ipilimumab (ipi) in PD-(L)1 refractory melanoma (RM).
 
Marc Isamu Uemura
No Relationships to Disclose
 
Cara L. Haymaker
Research Funding - Idera; Nektar
 
Ravi Murthy
No Relationships to Disclose
 
Marihella James
No Relationships to Disclose
 
Mark Cornfeld
Employment - Idera
Stock and Other Ownership Interests - Idera
Travel, Accommodations, Expenses - Idera
 
Srinivas Chunduru
Employment - Idera
Stock and Other Ownership Interests - Idera
Travel, Accommodations, Expenses - Idera
 
Sudhir Agrawal
Employment - Idera
Leadership - Idera
Stock and Other Ownership Interests - Idera
Patents, Royalties, Other Intellectual Property - Idera (Inst)
Travel, Accommodations, Expenses - Idera
 
Cassian Yee
No Relationships to Disclose
 
Jennifer A. Wargo
Leadership - Gklaxo Smithcline; Genetech; novartis; bristol myers squibb; illumina; Dava oncology
Honoraria - Gklaxo Smithcline; Genetech; novartis; bristol myers squibb; illumina; Dava oncology
Consulting or Advisory Role - Gklaxo Smithcline; Genetech; novartis; bristol myers squibb; illumina; DAVA oncology
Speakers' Bureau - Novartis; Genetech
Research Funding - BMS; Genetech; Novartis; GSK (Inst)
Travel, Accommodations, Expenses - Gklaxo Smithcline; Genetech; novartis; bristol myers squibb; illumina; Dava oncology
 
Rodabe Navroze Amaria
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst); Novartis (Inst)
 
Sapna Pradyuman Patel
Stock and Other Ownership Interests - Provectus
Honoraria - Dava Oncology; PCME, Rockpointe; PlatformQ Health
Consulting or Advisory Role - Amgen; Genentech/Roche
Speakers' Bureau - Bristol-Myers Squibb (Mexico); Merck
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Celldex (Inst); Deciphera (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Prometheus (Inst); Reata Pharmaceuticals (Inst)
 
Hussein Abdul-Hassan Tawbi
Consulting or Advisory Role - Novartis
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst); Novartis (Inst)
 
Isabella Claudia Glitza
Travel, Accommodations, Expenses - Lilly
 
Scott Eric Woodman
No Relationships to Disclose
 
Wen-Jen Hwu
Consulting or Advisory Role - Merck
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; MedImmune; Merck/Schering Plough
 
Michael A. Davies
Consulting or Advisory Role - Genentech/Roche; GlaxoSmithKline; Novartis; Sanofi; Vaccinex
Research Funding - AstraZeneca (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Myriad Genetics (Inst); Oncothyreon (Inst); Sanofi (Inst)
 
Patrick Hwu
Stock and Other Ownership Interests - immatics; Lion Biotechnologies
Consulting or Advisory Role - Lion Biotechnologies
Research Funding - Bristol-Myers Squibb (Inst); Genentech (Inst)
 
Willem W Overwijk
No Relationships to Disclose
 
Chantale Bernatchez
Employment - Lexicon (I)
Stock and Other Ownership Interests - Lexicon (I)
Consulting or Advisory Role - Lion Biotechnologies
Research Funding - Idera; Nektar
Patents, Royalties, Other Intellectual Property - Patent pending on BTLA as a marker for better CD8 T cells for adoptive immunotherapy
 
Adi Diab
Consulting or Advisory Role - Celgene; CureVac; Nektar
Research Funding - Celgene (Inst); Idera (Inst); Nektar (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Nektar